




IFW

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 22, 2007 Signature:  (Joseph A. Williams, Jr.)

Docket No.: 30610/39385A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Zankel et al.

Application No.: 10/588,425

Confirmation No.: 0

Filed: August 4, 2006

Art Unit: 0

For: MANUFACUTURE OF HIGHLY
PHOSPHORYLATED LYSOSOMAL
ENZYMES AND USES THEREOF

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR

1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30610/39385A.

Dated: March 22, 2007

Respectfully submitted,

By 

Joseph A. Williams, Jr.

Registration No.: 38,659

MARSHALL, GERSTEIN & BORUN LLP


233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	30610/39385A
-------	---	----	---	------------------------	--------------

Complete if Known

Application Number	10/588,425
Filing Date	August 4, 2006
First Named Inventor	Zankel et al.
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	30610/39385A

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-4,394,448	07-19-1983	Szoka, Jr. et al.	
		US-5,186,941	02-16-1993	Callahan et al.	
		US-5,962,012	10-05-1999	Lin et al.	
		US-6,261,595	07-17-2001	Stanley et al.	
		US-6,537,785	03-25-2003	Canfield	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Braulke et al., "On the Effects of Weak Bases and Monensin on Sorting and Processing of Lysosomal Enzymes in Human Cells," <i>Eur. J. Cell Biol.</i> , 43:316-321 (1987).	
		Hoogerbrugge et al., "Allogeneic Bone Marrow Transplantation for Lysosomal Storage Diseases. The European Group for Bone Marrow Transplantation," <i>Lancet</i> , 345:1398-1402 (1995).	
		Ioannou et al., "Overexpression of Human Alpha-galactosidase A Results in it's Intracellular Aggregation Crystallization in Lysosomes, and Selective Secretion," <i>J. Cell Biology</i> , 119:1137-1150 (1992).	
		Kakkis, "Enzyme Replacement Therapy for the Mucopolysaccharide Storage Disorders," <i>Expert Opin. Investig. Drugs</i> , 11:675-685 (2002).	
		Marnell et al., "A Chinese Hamster Ovary Cell with a Heat-sensitive, Conditional-lethal Defect in Vacuolar Function," <i>J. Cell Biol.</i> , 99:1907-1916 (1984).	
		Munier-Lehmann et al., "Function of the Two Mannose 6-Phosphate Receptors in Lysosomal Enzyme Transport," <i>Biochem. Soc. Trans.</i> , 24:133-136 (1996).	
		Nishi et al., "The Vacuolar (H ⁺)-ATPases--Nature's Most Versatile Proton Pumps," <i>Nat. Rev. Mol. Cell Biol.</i> , 3:94-103 (2002).	
		Park et al., "Biosynthesis of Lysosomal Enzymes in Cells of the END3 Complementation Group Conditionally Defective in Endosomal Acidifications," <i>Somatic Cell and Molecular Genetics</i> , 17:137-150 (1991).	
		Van Hove et al., "High Level Production of Recombinant Human Lysosomal Acid Alpha-glucosidase in Chinese Hamster Ovary Cells which Targets to Heart Muscle and Corrects Glycogen Accumulation in Fibroblasts from Patients with Pompe Disease," <i>Proc. Nat. Acad. Sci. (USA)</i> , 93:65-70 (1996).	

Examiner Signature	Date Considered
-----------------------	--------------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/588,425
				Filing Date	August 4, 2006
				First Named Inventor	Zankel et al.
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	2	of	2	Attorney Docket Number	30610/39385A

		Vellard, "The Enzyme as Drug: Application of Enzymes as Pharmaceuticals," <i>Current Opin. Biotech.</i> , 14:1-7 (2003).	
		Winchester et al., "The Molecular Basis of Lysosomal Storage Diseases and Their Treatment," <i>Biotech. Soc. Trans.</i> , 28:150-154 (2000).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--